Open call for evidence

Cannabis-based products for medicinal use

From:
Advisory Council on the Misuse of Drugs
Published
17 September 2025

Summary

Call for evidence to support ACMD's review of changes to legislation on the use of cannabis-based products for medicinal purposes (CBPMs).

This call for evidence closes at

Call for evidence description

The Advisory Council on the Misuse of Drugs (ACMD) is currently reviewing the impact of the 2018 changes to the Misuse of Drugs Regulations 2001 which included cannabis-based products for medicinal use (CBPMs).

CBPMs are cannabis-based products for medicinal use in humans, which have not been assessed by the medicines regulator.

The review will:

  • consider whether the legislation had the intended impact
  • identify unintended consequences
  • make recommendations on how to mitigate unintended consequences

The call is intended for:

  • healthcare professionals
  • researchers and academics
  • importers and manufacturers
  • individuals with lived or living experience
  • patients and families of patients
  • regulatory and enforcement bodies

Documents

Cannabis-based products for medicinal use: call for evidence

HTML

Cannabis-based products for medicinal use: downloadable questions

ODT, 9.26 KB

This file is in an OpenDocument format

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email alternativeformats@homeoffice.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Ways to respond

Respond online

or

Email to:

ACMD@homeoffice.gov.uk

Updates to this page

Published 17 September 2025

Sign up for emails or print this page